A Study of Famitinib in Patients With Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01762293

Recruitment Status : Completed

First Posted : January 7, 2013

Last Update Posted : April 18, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Peking University Cancer Hospital & Institute

Sun Yat-sen University

Information provided by (Responsible Party):

Jiangsu HengRui Medicine Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	September 2014
Actual Study Completion Date :	October 2014

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF, Lin LZ, Wang JW, Xiong JP, Wu CP, Li J, Liu YP, Wang D, Ba Y, Feng JP, Bai YX, Bi JW, Ma LW, Lei J, Yang Q, Yu H. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer. 2017 Dec 22;36(1):97. doi: 10.1186/s40880-017-0263-y.

To Top